Heidelberg Pharma AG

Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023

Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG: Heidelberg Pharma’s Partner Takeda Reached Development Milestone

Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics

Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy

Heidelberg Pharma reports on the results of the Annual General Meeting 2023

Heidelberg Pharma appoints Chief Financial Officer

Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023

Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023

Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business

Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform

Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022

Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022

Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study

EQS-DD: Heidelberg Pharma AG english

EQS-DD: Heidelberg Pharma AG english

EQS-DD: Heidelberg Pharma AG english

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022

Heidelberg Pharma AG Announces Adjustment of Guidance